NORCROSS, Ga., Aug. 17 /PRNewswire-FirstCall/ -- Immucor, Inc. , a global leader in providing automated instrument-reagent systems to the blood transfusion industry, announced today that it has signed a supply agreement with the American Red Cross for 19 Galileo systems for its five U.S. National Testing Laboratories.
"The American Red Cross is one of the largest and most prestigious health care organizations in the United States and these five laboratories test approximately seven million units of blood annually," said Dr. Gioacchino De Chirico, President and CEO of Immucor. "We are very pleased the American Red Cross has chosen the Galileo system for its laboratories. We expect these instruments to generate a total of at least $5 million a year in new reagent revenue after they are all live, depending on the amount and type of testing done on each instrument."
Founded in 1982, Immucor manufactures and sells a complete line of reagents and systems used by hospitals, reference laboratories and donor centers to detect and identify certain properties of the cell and serum components of blood prior to transfusion. Immucor markets a complete family of automated instrumentation for all of its market segments.
For more information on Immucor, please visit our website at http://www.immucor.com.
Statements contained in this press release that are not statements of historical fact are "forward-looking statements" as that term is defined under federal securities laws, including, without limitation, all statements concerning Immucor's expectations, beliefs, intentions or strategies for the future. Forward-looking statements may be identified by words such as "plans," "expects," "believes," "anticipates," "estimates," "projects," "will," "should" and other words of similar meaning. Investors are cautioned not to place undue reliance on any forward-looking statements. In particular, our financial results may be adversely impacted by the inability of the American Red Cross to effectively integrate our Galileo instruments into their blood testing operations. Further risks are detailed in the Company's filings with the Securities and Exchange Commission. Immucor assumes no obligation to update any forward-looking statements.
Immucor, Inc.CONTACT: Patrick Waddy of Immucor, Inc., +1-770-441-2051
Web site: http://www.immucor.com/
